Hubbry Logo
Beta cellBeta cellMain
Open search
Beta cell
Community hub
Beta cell
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Beta cell
Beta cell
Beta cell
View on Wikipedia
from Wikipedia

Beta cell
Details
LocationPancreatic islet
FunctionInsulin secretion
Identifiers
Latinendocrinocytus B; insulinocytus
MeSHD050417
THH3.04.02.0.00026
FMA85704
Anatomical terms of microanatomy
Human pancreatic islet by immunostaining. Nuclei of cells are shown in blue (DAPI). Beta cells are shown in green (Insulin), Delta cells are shown in white (Somatostatin).

Beta cells (β-cells) are specialized endocrine cells located within the pancreatic islets of Langerhans responsible for the production and release of insulin and amylin.[1] Constituting ~50–70% of cells in human islets, beta cells play a vital role in maintaining blood glucose levels.[2] Problems with beta cells can lead to disorders such as diabetes.[3]

Function

[edit]

The function of beta cells is primarily centered around the synthesis and secretion of hormones, particularly insulin and amylin. Both hormones work to keep blood glucose levels within a narrow, healthy range by different mechanisms.[4] Insulin facilitates the uptake of glucose by cells, allowing them to use it for energy or store it for future use.[5] Amylin helps regulate the rate at which glucose enters the bloodstream after a meal, slowing down the absorption of nutrients by inhibiting gastric emptying.[6]

Insulin synthesis

[edit]

Beta cells are the only site of insulin synthesis in mammals.[7] As glucose stimulates insulin secretion, it simultaneously increases proinsulin biosynthesis through translational control and enhanced gene transcription.[4][8]

The insulin gene is first transcribed into mRNA and translated into preproinsulin.[4] After translation, the preproinsulin precursor contains an N-terminal signal peptide that allows translocation into the rough endoplasmic reticulum (RER).[9] Inside the RER, the signal peptide is cleaved to form proinsulin.[9] Then, folding of proinsulin occurs forming three disulfide bonds.[9] Subsequent to protein folding, proinsulin is transported to the Golgi apparatus and enters immature insulin granules where proinsulin is cleaved to form insulin and C-peptide.[9] After maturation, these secretory vesicles hold insulin, C-peptide, and amylin until calcium triggers exocytosis of the granule contents.[4]

Through translational processing, insulin is encoded as a 110 amino acid precursor but is secreted as a 51 amino acid protein.[9]

Insulin secretion

[edit]
A diagram of the Consensus Model of glucose-stimulated insulin secretion
The triggering pathway of glucose-stimulated insulin secretion

In beta cells, insulin release is stimulated primarily by glucose present in the blood.[4] As circulating glucose levels rise, such as after ingesting a meal, insulin is secreted in a dose-dependent fashion.[4] This system of release is commonly referred to as glucose-stimulated insulin secretion (GSIS).[10] There are four key events to the triggering pathway of GSIS: GLUT dependent glucose uptake, glucose metabolism, KATP channel closure, and the opening of voltage gated calcium channels causing insulin granule fusion and exocytosis.[11][12]

Voltage-gated calcium channels and ATP-sensitive potassium ion channels (KATP channels) are embedded in the plasma membrane of beta cells.[12][13] Under non-glucose stimulated conditions, the KATP channels are open and the voltage gated calcium channels are closed.[4][14] Via the KATP channels, potassium ions move out of the cell, down their concentration gradient, making the inside of the cell more negative with respect to the outside (as potassium ions carry a positive charge).[4] At rest, this creates a potential difference across the cell surface membrane of -70mV.[15]

When the glucose concentration outside the cell is high, glucose molecules move into the cell by facilitated diffusion, down its concentration gradient through glucose transporters (GLUT).[16] Rodent beta cells primarily express the GLUT2 isoform, whereas human beta cells, although also expressing GLUT2, mainly make use of GLUT1 and GLUT3 isoforms.[17][18] Since beta cells use glucokinase to catalyze the first step of glycolysis, metabolism only occurs around physiological blood glucose levels and above.[4] Metabolism of glucose produces ATP, which increases the ATP to ADP ratio.[19]

The KATP channels close when the ATP to ADP ratio rises.[13] The closure of the KATP channels causes the outward potassium ion current to diminish, leading to inward currents of potassium ions dominating.[14] As a result, the potential difference across the membrane becomes more positive (as potassium ions accumulate inside the cell).[15] This change in potential difference opens the voltage-gated calcium channels, which allows calcium ions from outside the cell to move into the cell down their concentration gradient.[15] When the calcium ions enter the cell, they cause vesicles containing insulin to move to, and fuse with, the cell surface membrane, releasing insulin by exocytosis into the pancreatic capillaries.[20][21][22] The venous blood then eventually empties into the hepatic portal vein.[22]

In addition to the triggering pathway, the amplifying pathway can cause increased insulin secretion without a further increase in intracellular calcium levels. The amplifying pathway is modulated by byproducts of glucose metabolism along with various intracellular signaling pathways; incretin hormone signaling being one important example.[11][23]

Other hormones secreted

[edit]
  • C-peptide, which is secreted into the bloodstream in equimolar quantities to insulin. C-peptide helps to prevent neuropathy and other vascular deterioration related symptoms of diabetes mellitus.[24] A practitioner would measure the levels of C-peptide to obtain an estimate for the viable beta cell mass.[25]
  • Amylin, also known as islet amyloid polypeptide (IAPP).[26] The function of amylin is to slow the rate of glucose entering the bloodstream. Amylin can be described as a synergistic partner to insulin, where insulin regulates long term food intake and amylin regulates short term food intake.

Clinical significance

[edit]

Beta cells have significant clinical relevance as their proper function is essential for glucose regulation, and dysfunction is a key factor in the development and progression of diabetes and its associated complications.[27] Here are some key clinical significances of beta cells:

Type 1 diabetes

[edit]

Type 1 diabetes mellitus, also known as insulin-dependent diabetes, is believed to be caused by an auto-immune mediated destruction of the insulin-producing beta cells in the body.[9] The process of beta-cell destruction begins with insulitis activating antigen-presenting cells (APCs). APCs then trigger activation of CD4+ helper-T cells and chemokines/cytokines release. Then, the cytokines activate CD8+ cytotoxic–T cells which leads to beta-cell destruction.[28] The destruction of these cells reduces the body's ability to respond to glucose levels in the body, therefore making it nearly impossible to properly regulate glucose and glucagon levels in the bloodstream.[29] The body destroys 70–80% of beta cells, leaving only 20–30% of functioning cells.[2][30] This can cause the patient to experience hyperglycemia, which leads to other adverse short-term and long-term conditions.[31] The symptoms of diabetes can potentially be controlled with methods such as regular doses of insulin and sustaining a proper diet.[31] However, these methods can be tedious and cumbersome to continuously perform on a daily basis.[31]

Type 2 diabetes

[edit]

Type 2 diabetes, also known as non insulin dependent diabetes and as chronic hyperglycemia, is caused primarily by genetics and the development of metabolic syndrome.[2][9] The beta cells can still secrete insulin but the body has developed a resistance and its response to insulin has declined.[4] It is believed to be due to the decline of specific receptors on the surface of the liver, adipose, and muscle cells which lose their ability to respond to insulin that circulates in the blood.[32][33] In an effort to secrete enough insulin to overcome the increasing insulin resistance, the beta cells increase their function, size and number.[4] Increased insulin secretion leads to hyperinsulinemia, but blood glucose levels remain within their normal range due to the decreased efficacy of insulin signaling.[4] However, the beta cells can become overworked and exhausted from being overstimulated, leading to a 50% reduction in function along with a 40% decrease in beta-cell volume.[9] At this point, not enough insulin can be produced and secreted to keep blood glucose levels within their normal range, causing overt type 2 diabetes.[9]

Insulinoma

[edit]

Insulinoma is a rare tumor derived from the neoplasia of beta cells. Insulinomas are usually benign, but may be medically significant and even life-threatening due to recurrent and prolonged attacks of hypoglycemia.[34]

Medications

[edit]

Many drugs to combat diabetes are aimed at modifying the function of the beta cell.

  • Sulfonylureas are insulin secretagogues that act by closing the ATP-sensitive potassium channels, thereby causing insulin release.[35][36] These drugs are known to cause hypoglycemia and can lead to beta-cell failure due to overstimulation.[2] Second-generation versions of sulfonylureas are shorter acting and less likely to cause hypoglycemia.[36]
  • GLP-1 receptor agonists stimulate insulin secretion by simulating activation of the body's endogenous incretin system.[36] The incretin system acts as an insulin secretion amplifying pathway.[36]
  • DPP-4 inhibitors block DPP-4 activity which increases postprandial incretin hormone concentration, therefore increasing insulin secretion.[36]

Research

[edit]

Experimental techniques

[edit]

Many researchers around the world are investigating the pathogenesis of diabetes and beta-cell failure. Tools used to study beta-cell function are expanding rapidly with technology.

For instance, transcriptomics have allowed researchers to comprehensively analyze gene transcription in beta-cells to look for genes linked to diabetes.[2] A more common mechanism of analyzing cellular function is calcium imaging. Fluorescent dyes bind to calcium and allow in vitro imaging of calcium activity which correlates directly with insulin release.[2][37] A final tool used in beta-cell research are in vivo experiments. Diabetes mellitus can be experimentally induced in vivo for research purposes by streptozotocin[38] or alloxan,[39] which are specifically toxic to beta cells. Mouse and rat models of diabetes also exist including ob/ob and db/db mice which are a type 2 diabetes model, and non-obese diabetic mice (NOD) which are a model for type 1 diabetes.[40]

Type 1 diabetes

[edit]

Research has shown that beta cells can be differentiated from human pancreas progenitor cells.[41] These differentiated beta cells, however, often lack much of the structure and markers that beta cells need to perform their necessary functions.[41] Examples of the anomalies that arise from beta cells differentiated from progenitor cells include a failure to react to environments with high glucose concentrations, an inability to produce necessary beta cell markers, and abnormal expression of glucagon along with insulin.[41]

In order to successfully re-create functional insulin producing beta cells, studies have shown that manipulating cell-signal pathways in early stem cell development will lead to those stem cells differentiating into viable beta cells.[41][42] Two key signal pathways have been shown to play a vital role in the differentiation of stem cells into beta cells: the BMP4 pathway and the kinase C.[42] Targeted manipulation of these two pathways has shown that it is possible to induce beta cell differentiation from stem cells.[42] These variations of artificial beta cells have shown greater levels of success in replicating the functionality of natural beta cells, although the replication has not been perfectly re-created yet.[42]

Studies have shown that it is possible to regenerate beta cells in vivo in some animal models.[43] Research in mice has shown that beta cells can often regenerate to the original quantity number after the beta cells have undergone some sort of stress test, such as the intentional destruction of the beta cells in the mice subject or once the auto-immune response has concluded.[41] While these studies have conclusive results in mice, beta cells in human subjects may not possess this same level of versatility. Investigation of beta cells following acute onset of Type 1 diabetes has shown little to no proliferation of newly synthesized beta cells, suggesting that human beta cells might not be as versatile as rat beta cells, but there is actually no comparison that can be made here because healthy (non-diabetic) rats were used to prove that beta cells can proliferate after intentional destruction of beta cells, while diseased (type-1 diabetic) humans were used in the study which was attempted to use as evidence against beta cells regenerating.[44]

It appears that much work has to be done in the field of regenerating beta cells.[42] Just as in the discovery of creating insulin through the use of recombinant DNA, the ability to artificially create stem cells that would differentiate into beta cells would prove to be an invaluable resource to patients with Type 1 diabetes. An unlimited amount of beta cells produced artificially could potentially provide therapy to many of the patients who are affected by Type 1 diabetes.

Type 2 diabetes

[edit]

Research focused on non insulin dependent diabetes encompasses many areas of interest. Degeneration of the beta cell as diabetes progresses has been a broadly reviewed topic.[2][4][9] Another topic of interest for beta-cell physiologists is the mechanism of insulin pulsatility which has been well investigated.[45][46] Many genome studies have been completed and are advancing the knowledge of beta-cell function exponentially.[47][48] Indeed, the area of beta-cell research is very active yet many mysteries remain.

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Beta cell

View on Grokipedia
from Grokipedia
Beta cells, also known as β-cells, are specialized endocrine cells located within the clusters of cells called the islets of Langerhans in the . They serve as the of insulin, a that is crucial for maintaining by promoting the uptake and utilization of glucose in peripheral tissues. In humans, beta cells constitute the majority of cells in the pancreatic islets, where they are intermixed with other endocrine cell types such as alpha and delta cells, differing from the more centralized arrangement observed in . The core function of beta cells involves sensing fluctuations in blood glucose levels and responding with precise insulin secretion to prevent hyperglycemia. This glucose-sensing mechanism begins with the uptake of glucose via glucose transporters (primarily GLUT2 in rodents and GLUT1 in humans) on the beta cell membrane, followed by phosphorylation by the enzyme glucokinase, which acts as a glucose sensor due to its high Km value matching physiological glucose concentrations. Subsequent metabolism in the mitochondria increases the ATP/ADP ratio, leading to closure of ATP-sensitive potassium channels, membrane depolarization, influx of calcium ions through voltage-gated channels, and ultimately the exocytosis of insulin-containing secretory granules. This tightly regulated process ensures that insulin release is proportional to nutrient availability, supporting metabolic balance during fed and fasted states. Beta cells are vital for overall metabolic health, but their dysfunction or destruction underlies major endocrine disorders, particularly diabetes mellitus. In , autoimmune attack leads to the near-complete loss of beta cells, resulting in absolute insulin deficiency. In , beta cells initially compensate for by increasing secretion, but progressive cellular stress, deposition, and cause a gradual decline in function and mass. Ongoing research focuses on beta cell regeneration and protection as potential therapeutic strategies to restore glucose control in these conditions.

Anatomy and Distribution

Location in the Pancreas

Beta cells are primarily located within the islets of Langerhans, which are spherical clusters of endocrine cells embedded throughout the exocrine tissue of the . These islets constitute approximately 1-2% of the total pancreatic and are richly vascularized to facilitate release into the bloodstream. In the human , there are approximately 1 million islets, each containing 1,000 to 3,000 cells, with beta cells comprising 50-70% of the total islet cell population. The density of islets is unevenly distributed, being higher in the and body regions compared to the head, where the islet area proportion is about 1.06% in the head, 1.09% in the body, and 1.47% in the . This regional variation reflects differences in developmental origins, with the deriving primarily from the dorsal pancreatic bud. The islets were first described in 1869 by , a German medical student, who identified these distinct cellular clusters in the during his doctoral thesis. In the early 20th century, following the 1921 discovery of insulin, beta cells were confirmed as the insulin-producing population through histological staining techniques, such as Gomori's aldehyde fuchsin method developed in 1950, which specifically targeted insulin granules in these cells. Pancreatic islet architecture exhibits evolutionary conservation across mammals, with beta cells forming a central core in islets, while in humans they are more intermixed with other endocrine cells, and appear dispersed in such as dogs and pigs. This organization supports coordinated endocrine function, despite interspecies variations in cell mixing.

Cellular Composition and Morphology

Beta cells are polygonal endocrine cells typically measuring 10-20 μm in diameter, characterized by a large central nucleus, extensive , prominent Golgi apparatus, and numerous secretory granules. The abundant rER and Golgi reflect their specialization for protein synthesis and processing, essential for production. These cells are primarily distributed within the of Langerhans. Electron microscopy of beta cells reveals dense-core secretory granules, approximately 200-350 nm in diameter, containing crystalline arrays of insulin hexamers arranged in rhomboidal lattices. The resting of these cells is approximately -70 mV, maintained by activity. Beta cells are identified histologically using Latin such as endocrinocytus B or insulinocytus, and they stain positively with aldehyde fuchsin for their granules or via immunolabeling for insulin. Beta cells exhibit heterogeneity in size and granule density, influenced by factors such as age and metabolic state; for instance, nuclear size and increase under metabolic stress, while granule content varies with physiological conditions. This variability underscores their adaptive structural features, though detailed functional subtypes are addressed elsewhere.

of Hormones

Insulin Synthesis Pathway

The insulin synthesis pathway in pancreatic beta cells commences with the transcription of the INS gene, located on the short arm of in humans. This gene encodes preproinsulin mRNA, which is translated on ribosomes associated with the (rER) into a 110-amino-acid precursor protein known as preproinsulin. Upon entry into the rER lumen, the N-terminal 24-amino-acid is rapidly cleaved by signal peptidase, yielding proinsulin, an 86-amino-acid polypeptide comprising the B-chain, , and A-chain connected by dibasic residues. Proinsulin then folds, forming three disulfide bonds essential for its structure: two interchain bonds between the A and B chains, and one intrachain bond in the A chain. This folded proinsulin is transported via vesicles to the Golgi apparatus and subsequently to the trans-Golgi network (TGN). In the immature secretory granules budding from the TGN, proinsulin undergoes proteolytic processing mediated by the prohormone convertases PC1/3 (also known as PC3) and PC2, in concert with carboxypeptidase E. PC1/3 primarily cleaves the B-C junction, while PC2 targets the A-C junction and completes the B-C cleavage, excising the 31-amino-acid and generating mature insulin—a 51-amino-acid heterodimer with the 21-amino-acid A chain and 30-amino-acid B chain linked by the disulfide bridges. The excised remains associated with insulin during storage. This processing occurs progressively as granules mature, with endoproteolytic cleavages followed by exopeptidase removal of C-terminal basic residues (lysine-arginine pairs). Glucose metabolism in beta cells upregulates INS gene transcription through the activation and nuclear translocation of key transcription factors, including PDX1 (pancreatic and duodenal 1), which binds to enhancer elements in the INS promoter to enhance expression; other factors such as MafA and NeuroD1 cooperate in this glucose-responsive regulation. On average, each beta cell synthesizes approximately 10^8 insulin molecules daily to maintain steady-state levels and meet physiological demands. Mature insulin and are concentrated and packaged into secretory granules, where ions (Zn²⁺) are co-transported via the ZnT8 transporter, promoting the assembly of insulin into stable hexamers that crystallize for efficient storage; these hexamers, with two Zn²⁺ ions per hexamer, occupy a significant portion of the granule volume. is stored equimolar to insulin within these granules and is co-secreted upon , serving as a marker of endogenous insulin production.

Synthesis of Other Hormones

In addition to insulin, pancreatic beta cells synthesize and secrete several other hormones and peptides, most notably , also known as islet amyloid polypeptide (IAPP). is encoded by the IAPP gene located on 12q24.2 in humans and is produced as a 67-amino-acid precursor protein, proIAPP, which undergoes post-translational processing within the secretory granules of beta cells. This processing mirrors that of proinsulin, involving cleavage by prohormone convertases to yield the mature 37-amino-acid peptide, which is then packaged alongside insulin. Amylin is co-synthesized and stored with insulin in the same secretory granules of beta cells, typically at a molar ratio of approximately 1:100 relative to insulin, though this can vary between 1:10 and 1:100 depending on physiological conditions. Its synthesis is upregulated by glucose stimulation, similar to insulin, leading to co-release during nutrient-responsive secretion. As a byproduct of insulin biosynthesis, C-peptide is generated in equimolar amounts to insulin during the cleavage of proinsulin in beta cell granules, serving as a reliable for endogenous insulin production rather than functioning as a itself. In pathological contexts, such as , amylin can misfold and aggregate into fibrils, contributing to beta cell dysfunction through the formation of extracellular deposits, though the precise mechanisms of remain under investigation.

Mechanisms of Secretion

Glucose-Stimulated Insulin Secretion

Glucose-stimulated insulin secretion (GSIS) is the primary mechanism by which pancreatic beta cells respond to elevated blood glucose levels, enabling the regulation of systemic glucose homeostasis. In this process, glucose enters the beta cell primarily through facilitative glucose transporters. In rodents, glucose uptake occurs predominantly via GLUT2, a low-affinity, high-capacity transporter with a KmK_m around 17 mM, allowing equilibration of glucose across the plasma membrane. In human beta cells, however, GLUT1 predominates as the primary glucose transporter (Km ~6 mM), with GLUT2 expressed in a subpopulation of cells (~13% coexpress with GLUT1), enabling efficient uptake at physiological concentrations. Once inside the cell, glucose undergoes and subsequent mitochondrial oxidation, leading to increased production of ATP. This rise in the ATP/ADP ratio inhibits ATP-sensitive potassium (KATP) channels, which are hetero-octameric complexes composed of four Kir6.2 pore-forming subunits and four SUR1 regulatory subunits located on the plasma membrane. Closure of these channels reduces the outward potassium current, described by the simplified equation for KATP conductance: IKATP=gKATP⋅(Vm−EK)I_{K_{ATP}} = g_{K_{ATP}} \cdot (V_m - E_K) where IKATPI_{K_{ATP}} is the current, gKATPg_{K_{ATP}} is the channel conductance, VmV_m is the , and EKE_K is the equilibrium potential; inhibition decreases gKATPg_{K_{ATP}}, thereby limiting IKATPI_{K_{ATP}} and causing . activates voltage-gated calcium channels, primarily L-type, allowing influx of extracellular Ca²⁺ into the . This in intracellular Ca²⁺ concentration serves as the key trigger for insulin granule , where docked secretory granules fuse with the plasma to release insulin. GSIS exhibits a characteristic biphasic pattern: the first phase is rapid and transient, reflecting the release of a readily releasable pool of granules near the , while the second phase is sustained, involving recruitment and of additional granules from the reserve pool. The glucose threshold for initiating GSIS is approximately 5 mM, corresponding to glucose levels, with half-maximal secretion occurring around 8-10 mM and maximal rates achieved at 20-25 mM, ensuring insulin release is finely tuned to postprandial glucose excursions.

Regulation of Secretion

The regulation of beta cell secretion involves multiple modulatory mechanisms that fine-tune insulin release beyond the core glucose-stimulated insulin secretion (GSIS) pathway. Incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play a central role in amplifying GSIS. These gut-derived hormones are released in response to nutrient ingestion and bind to G protein-coupled receptors on beta cells, activating Gs protein signaling that elevates cyclic AMP (cAMP) levels. The subsequent activation of protein kinase A (PKA) enhances the sensitivity of the exocytotic machinery to calcium ions (Ca²⁺), thereby potentiating insulin granule release without directly altering glucose metabolism. This incretin effect accounts for up to 60% of the postprandial insulin response in healthy individuals, underscoring its physiological importance. Autocrine and paracrine signals within the microenvironment provide additional layers of control to prevent excessive insulin secretion. Secreted insulin acts in an autocrine manner by binding to insulin receptors on the same or neighboring beta cells, activating (PI3K) pathways that inhibit further insulin release and promote beta cell rest. This helps maintain secretory during prolonged stimulation. Paracrine inhibition is mediated by released from adjacent delta cells, which binds to somatostatin receptors (SSTRs) on beta cells, suppressing cAMP production and thereby dampening insulin secretion to coordinate hormone output. Delta cell-derived somatostatin exerts a tonic inhibitory tone, facilitating synchronized responses to metabolic cues. Neural and hormonal inputs further modulate beta cell activity in response to systemic signals. Parasympathetic innervation via the stimulates insulin secretion through release, which activates muscarinic receptors on beta cells to increase intracellular Ca²⁺ and enhance . In contrast, sympathetic activation, such as during stress, inhibits insulin release; adrenaline binds to α₂-adrenergic receptors on beta cells, coupling to proteins that reduce cAMP levels and hyperpolarize the via K⁺ channel activation. Circulating free fatty acids also potentiate GSIS by activating the 40 (GPR40), which triggers signaling to amplify Ca²⁺ signaling and insulin granule fusion. This nutrient-sensing mechanism links lipid availability to secretory enhancement under fed conditions. Long-term feedback mechanisms protect beta cells from overactivation but can lead to adaptive changes. Chronic exposure to elevated glucose levels induces glucotoxicity, characterized by downregulation of insulin gene transcription and impaired secretory responsiveness through and stress pathways. This desensitization manifests as reduced GSIS efficiency, serving as a protective response to prevent exhaustion but contributing to progressive beta cell dysfunction if unresolved.

Physiological Functions

Role in Glucose Homeostasis

Beta cells play a central role in maintaining by secreting insulin in response to elevated blood glucose levels, thereby preventing and ensuring euglycemia. In the state, blood glucose is typically maintained between 4 and 6 mM, while postprandial levels are controlled to remain below 8 mM through timely insulin release. Insulin acts primarily by promoting glucose uptake into peripheral tissues such as and via translocation of the transporter to the cell membrane, facilitating the conversion of glucose to for storage. Additionally, insulin inhibits hepatic glucose output by suppressing and in the liver, thereby reducing endogenous glucose production during periods of nutrient excess. Following a meal, beta cells detect the rise in circulating glucose—primarily arterial levels augmented by signals from glucose sensors—and initiate insulin secretion to match the influx of nutrients. This postprandial response ensures rapid restoration of euglycemia by enhancing glucose disposal and curbing hepatic glucose release. In healthy adults, the total beta cell mass is approximately 1 g, enabling basal insulin secretion of 1-2 units per hour to sustain fasting glucose control, with surges up to 10 units during meals to handle the increased glucose load. Complementing insulin, beta cells co-secrete , a that further supports by slowing gastric emptying to moderate absorption and suppressing postprandial glucagon secretion from alpha cells, thus preventing inappropriate hepatic glucose mobilization. This coordinated action of insulin and fine-tunes the post-meal glycemic excursion, promoting efficient energy storage without excessive blood glucose fluctuations.

Interactions with Other Cell Types

Beta cells, constituting the majority of cells within , engage in intricate with neighboring endocrine cell types to fine-tune release and maintain glucose . Alpha cells secrete , which acts locally on beta cells to potentiate glucose-stimulated insulin secretion through of glucagon receptors and, to a lesser extent, GLP-1 receptors on beta cell surfaces. This paracrine stimulation is particularly evident during moderate , where intraislet glucagon enhances beta cell responsiveness without causing systemic effects. Delta cells release , a potent inhibitor of insulin from beta cells, mediated by somatostatin receptors that reduce cAMP levels and calcium influx in beta cells. This inhibitory feedback helps prevent excessive insulin release and coordinates islet responses to nutrient fluctuations. Pancreatic polypeptide (PP) cells, though less abundant, contribute to islet communication by secreting PP, which exerts insulinostatic effects on beta cells and may support beta cell turnover under physiological conditions. Beyond endocrine neighbors, beta cells interact closely with the islet vasculature, which features a dense network of fenestrated capillaries that facilitate rapid delivery of insulin directly into the hepatic . Beta cells actively promote this vascular architecture by secreting (VEGF-A), which induces endothelial and fenestration to ensure efficient nutrient sensing and hormone export. In turn, endothelial cells provide reciprocal signals, such as and other angiogenic factors, that regulate beta cell mass, survival, and function, thereby linking vascular integrity to islet health. Extrapancreatic interactions extend beta cell influence through hormonal crosstalk with distant tissues, notably the gut. Enteroendocrine cells in the intestine release incretins like (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in response to , which travel via the bloodstream to bind receptors on beta cells and amplify glucose-dependent insulin secretion while promoting beta cell proliferation and . Within the pancreatic microenvironment, immune cells also play a supportive role; regulatory T cells (Tregs) infiltrate islets and maintain to beta cells by suppressing autoreactive responses and fostering an milieu. Intra-islet coordination is further enabled by direct physical connections among beta cells via gap junctions composed primarily of connexin 36 (Cx36). These channels permit electrical coupling, allowing synchronized calcium oscillations and pulsatile insulin release across the beta cell network, which enhances the efficiency and uniformity of secretory responses to glucose stimuli. Disruption of Cx36-mediated coupling leads to desynchronized activity and impaired insulin dynamics, underscoring its essential role in collective beta cell behavior.

Pathological Conditions

Autoimmune Destruction in Type 1 Diabetes

Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing beta cells in the pancreatic islets, leading to absolute insulin deficiency. This process is primarily mediated by autoreactive T cells, particularly CD8+ cytotoxic T cells, which infiltrate the islets and target specific beta cell antigens such as insulin, glutamic acid decarboxylase 65 (GAD65), and insulinoma-associated antigen-2 (IA-2). These T cells recognize peptide epitopes presented on the surface of beta cells via major histocompatibility complex class I molecules, triggering cytotoxic responses that release perforin and granzymes to induce beta cell apoptosis. By the time of clinical diagnosis, approximately 70-80% of the beta cell mass has been lost, resulting in hyperglycemia and the need for exogenous insulin therapy. Genetic predisposition plays a central role in T1D susceptibility, with strong associations to specific (HLA) alleles, notably HLA-DR3 and haplotypes. Individuals heterozygous for DR3/DR4 exhibit the highest risk, as these alleles influence and T cell activation against beta cell autoantigens. Environmental factors, including viral infections, are thought to trigger the autoimmune response in genetically susceptible individuals; enteroviruses such as B have been implicated through molecular , where viral proteins cross-react with beta cell antigens, initiating or accelerating insulitis. These triggers likely interact with genetic factors to break , leading to the expansion of autoreactive T cell clones. The progression of beta cell destruction involves insulitis, an inflammatory infiltrate composed predominantly of CD8+ and CD4+ T cells, along with macrophages and B cells, that surrounds and penetrates the islets. This chronic inflammation gradually erodes beta cell function over months to years before . Recent studies have shown that dysfunction in remaining beta cells can occur independently of insulitis, contributing to early impairment in insulin secretion. Following and initiation of insulin therapy, many patients experience a "honeymoon phase," a transient period of partial remission where residual beta cells regain some function, reducing insulin requirements; this phase typically lasts 3-12 months and reflects the survival of a subset of beta cells not yet fully destroyed. Epidemiologically, T1D most commonly onset in childhood or , with global incidence rising over recent decades at an average annual rate of 3-4%, attributed to environmental and factors influencing susceptible populations.

Dysfunction in Type 2 Diabetes

In (T2D), beta cell dysfunction arises primarily from metabolic overload, leading to progressive impairment in insulin secretion and eventual beta cell exhaustion. Chronic exposure to elevated glucose levels, known as glucotoxicity, and free fatty acids, termed , overtaxes beta cells, disrupting their ability to maintain . This exhaustion manifests as reduced insulin responsiveness to stimuli, contributing to that further exacerbates the cycle. , in particular, induces beta cell demise through prolonged exposure to excess lipids, which impairs insulin secretion and promotes in human and animal models. A key pathological feature in T2D is the accumulation of amyloid polypeptide (IAPP) deposits, which form toxic aggregates that impair beta cell function and viability. These , derived from misfolded IAPP co-secreted with insulin, lead to beta cell and , reducing beta cell mass by approximately 40-60% in affected individuals compared to non-diabetic controls. This mass loss correlates with disease duration and severity, underscoring IAPP's role in accelerating beta cell failure. Underlying these changes are multiple cellular mechanisms, including endoplasmic reticulum (ER) stress, oxidative damage, and dedifferentiation. ER stress arises from the high protein synthesis demand in beta cells, activating the unfolded protein response that, if unresolved, triggers apoptosis; oxidative damage from reactive oxygen species further compromises mitochondrial function and insulin granule integrity. Dedifferentiation involves the loss of key transcription factors like PDX1 and MAFA, causing beta cells to revert to a progenitor-like state with diminished insulin production, while chronic hypersecretion leads to degranulation and depleted insulin stores. These processes collectively drive beta cell failure. However, recent research has demonstrated that functional recovery of beta cells is possible in human T2D, suggesting that some aspects of dysfunction may be reversible. Risk factors such as and genetic predispositions amplify this dysfunction. promotes , increasing beta cell workload and , while variants in the TCF7L2 gene, the strongest genetic risk factor for T2D, impair beta cell proliferation and insulin secretion by disrupting Wnt signaling pathways. The disease typically progresses from peripheral to overt beta cell failure over 10-15 years, with early compensatory giving way to secretory deficits. Recent studies highlight beta cell heterogeneity as a contributor to variable dysfunction in T2D, with subpopulations exhibiting differential susceptibility to stress and impaired secretory capacity. For instance, genetic analyses from 2022 onward reveal that heterogeneous enhancer states and transcriptomic profiles in beta cells influence their response to metabolic demands, leading to uneven progression of dysfunction across islets. This variability may explain differences in disease onset and response to therapies. Single-cell RNA sequencing (scRNA-seq) studies have further elucidated these changes in T2D pancreatic islets, demonstrating increased β cell heterogeneity with upregulation of dedifferentiation markers such as ALDH1A3 and activation of stress pathways. Additionally, α cells and endothelial cells exhibit significant microenvironmental alterations that impact overall islet function, while immune cells, including macrophages, infiltrate the islets and activate key inflammation pathways contributing to T2D progression. Multimodal approaches combining scRNA-seq and single-cell ATAC-seq (scATAC-seq) have revealed underlying epigenetic regulatory mechanisms driving these dysfunctions.

Neoplastic Disorders like Insulinoma

Insulinomas are rare pancreatic neuroendocrine tumors originating from beta cells, with an annual incidence of 1 to 4 cases per million individuals. These tumors cause endogenous , leading to recurrent due to excessive insulin secretion independent of blood glucose levels. Approximately 90% of insulinomas are benign, while the remaining 10% are malignant, with the latter often presenting more aggressive behavior and potential for . About 5-10% of insulinomas are associated with (MEN1) syndrome, an autosomal dominant disorder caused by germline mutations in the MEN1 . Pathologically, insulinomas arise from monoclonal proliferation of beta cells within the , resulting in well-differentiated neuroendocrine neoplasms that express insulin and chromogranin A. In cases linked to , biallelic inactivation of the MEN1 gene disrupts menin protein function, promoting uncontrolled beta cell growth and tumor formation. Clinically, patients typically present with , characterized by symptoms of (such as sweating, tremors, confusion, or seizures), documented low plasma glucose levels (usually below 50 mg/dL or 2.8 mmol/L), and prompt resolution of symptoms upon glucose administration. These neuroglycopenic and adrenergic symptoms often occur during fasting or postprandially, reflecting the tumor's autonomous insulin release. Diagnosis of insulinoma relies on biochemical confirmation during a supervised 72-hour fast, where is accompanied by inappropriately elevated insulin levels (>3 μU/mL) and (>0.6 ng/mL), distinguishing it from exogenous insulin administration. Imaging modalities, such as or CT/MRI, are used for localization, though small tumors (<1 cm) may require intraoperative ultrasonography for detection. Genetic testing for MEN1 mutations is recommended in younger patients or those with family history, as it influences for associated tumors. Beyond insulinomas, neoplastic-like hyperfunction of beta cells can manifest as , a rare condition involving diffuse beta cell and neogenesis, leading to persistent hyperinsulinemic in adults. Unlike typical , nesidioblastosis features dysplastic islets budding from pancreatic ducts without discrete masses, potentially progressing to insulinoma in some cases due to underlying genetic alterations. In adults, it is infrequently linked to genetic defects, such as mutations in genes (e.g., ABCC8 or KCNJ11), though environmental factors may also contribute to this non-neoplastic proliferation. Diagnosis often requires histopathological examination post-resection, as imaging may not distinguish it from insulinoma.

Therapeutic Interventions

Pharmacological Agents Targeting Beta Cells

represent a cornerstone class of pharmacological agents targeting beta cells in the management of (T2D). These drugs, such as glipizide, exert their primary effect by binding to the sulfonylurea receptor (SUR) subunit of ATP-sensitive (KATP) channels on pancreatic beta cells, leading to channel closure. This closure depolarizes the beta cell membrane, opening voltage-gated calcium channels and triggering calcium influx, which stimulates insulin independent of glucose levels. Glipizide, a second-generation , specifically promotes insulin release from beta cells while also reducing hepatic glucose output and enhancing peripheral insulin sensitivity. Widely used in T2D to improve glycemic control, carry a notable risk of as a , occurring due to excessive insulin even at low glucose concentrations, with rates higher than many other antidiabetic agents. Glucagon-like peptide-1 (GLP-1) receptor agonists, exemplified by , offer a glucose-dependent mechanism to enhance beta cell function. Approved by the U.S. in 2017 for T2D treatment, activates GLP-1 receptors on beta cells, potentiating glucose-stimulated insulin secretion (GSIS) by increasing cyclic AMP levels and amplifying the incretin effect. These agents also promote beta cell proliferation and survival, as evidenced by 's upregulation of PDX-1 expression, a key for beta cell maintenance. Cardiovascular outcome trials, including analyses up to 2020, have demonstrated that GLP-1 agonists like reduce major adverse cardiovascular events, such as and , in patients with T2D and established . Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, indirectly support beta cell health by mitigating glucotoxicity through renal glucose excretion and blood glucose lowering. By reducing , dapagliflozin alleviates stress and oxidative damage in beta cells, preserving insulin secretion and preventing functional decline in models of T2D. This protective effect restores beta cell mass and function without directly interacting with beta cell receptors. Dipeptidyl peptidase-4 (DPP-4) inhibitors complement incretin-based therapies by prolonging the activity of endogenous GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). These agents inhibit DPP-4 enzymatic degradation of incretins, elevating their plasma levels to enhance GSIS from beta cells in a glucose-dependent manner and suppress glucagon release from alpha cells. Among emerging agents, metformin acts as an AMP-activated protein kinase (AMPK) activator that improves beta cell sensitivity to glucose and protects against lipotoxicity and dysfunction. By activating AMPK in beta cells, metformin reduces reactive oxygen species production and enhances insulin secretion efficiency, contributing to sustained glycemic control in T2D. This mechanism positions metformin as a foundational therapy that indirectly bolsters beta cell resilience, though long-term use requires monitoring for potential gastrointestinal side effects.

Surgical and Other Treatments

Pancreas and transplantation represent established surgical interventions for restoring beta cell function in patients with (T1D), where autoimmune destruction leads to insulin deficiency. Whole transplantation, often performed simultaneously with in patients with end-stage renal disease, provides a complete replacement of the endocrine and exocrine , achieving insulin in approximately 80-90% of recipients at one year post-transplant. However, this procedure carries significant surgical risks, including vascular and , and requires lifelong to prevent allograft rejection. transplantation, a less invasive alternative, involves infusing donor-derived pancreatic into the for engraftment in the liver, thereby restoring endogenous insulin production. In June 2023, the FDA approved donislecel (Lantidra), an allogeneic islet product, for adults with T1D and severe unawareness who have had a transplant or are not eligible for it, improving access to this therapy. The protocol, introduced in 2000, marked a pivotal advancement by using a steroid-free immunosuppressive regimen with , , and , enabling insulin in 7 of 7 initial recipients for at least one year. Long-term outcomes have shown sustained insulin in approximately 30-50% of patients at five years, depending on the protocol and patient selection, though many require additional infusions due to progressive graft loss from immune-mediated attrition and nonimmune factors like deposition. Despite these improvements, challenges persist, including donor shortages, the need for multiple donors, and chronic side effects such as and risk. Surgical management of , a rare beta cell causing hyperinsulinemic , primarily involves tumor resection to achieve cure. For benign insulinomas, which constitute over 90% of cases, enucleation—the surgical removal of the tumor while preserving surrounding pancreatic tissue—is the preferred approach for lesions smaller than 2 cm, offering a high success rate with minimal endocrine or exocrine insufficiency. This parenchyma-sparing technique is feasible laparoscopically or robotically, reducing recovery time and complications compared to more extensive resections. For larger or multifocal tumors, partial (e.g., distal or en bloc resection) may be necessary, particularly if is suspected. Surgical excision cures approximately 90% of benign insulinomas, with recurrence rates below 5% in long-term follow-up, though malignant cases require additional oncologic therapies. Preoperative localization via or intraoperative palpation ensures precise intervention, underscoring surgery's role as the definitive treatment. Bariatric surgery offers a metabolic intervention for (T2D), where beta cell dysfunction contributes to , by promoting substantial and alleviating glucotoxicity. Procedures such as Roux-en-Y gastric bypass or induce rapid glycemic improvements, often leading to diabetes remission in 60-80% of patients within two years, independent of alone. This benefit arises from enhanced beta cell function, including improved insulin secretion and sensitivity to glucose, as well as evidence of partial beta cell mass recovery through reduced stress and . Sustained post-surgery "rests" overworked beta cells, allowing functional regeneration, though long-term durability varies with adherence to changes. These outcomes highlight bariatric surgery's potential as a non-pharmacological strategy to preserve residual beta cell capacity in obese T2D patients. Device-based therapies and emerging bioengineered approaches aim to mimic or replace beta cell without invasive surgery. Closed-loop insulin delivery systems, commonly known as artificial pancreas devices, integrate continuous glucose monitoring with automated insulin pumps to replicate the beta cell's real-time glucose-responsive insulin secretion, reducing and improving time in target glycemic range by 10-15% compared to sensor-augmented pumps. These hybrid systems, approved for clinical use, adjust basal insulin dynamically but require user input for meals, advancing toward fully automated versions. In parallel, clinical trials of bioengineered islets—derived from stem cells and encapsulated to evade immune rejection—seek to provide beta cell replacement without . Early phase 1/2 studies, including 2025 data from trials like Vertex's VX-880 and VX-264, have demonstrated insulin production, glycemic control, and insulin independence in T1D patients for up to one year or more, with encapsulated versions aiming to avoid . These innovations complement transplantation by offering scalable, patient-specific solutions for beta cell restoration.

Research and Future Directions

Experimental Models and Techniques

Experimental models for studying beta cells encompass a range of and approaches that enable detailed investigation of their function, signaling, and responses to physiological and pathological conditions. In vitro systems provide controlled environments to dissect cellular mechanisms, while in vivo models recapitulate systemic interactions relevant to . These techniques, combined with advanced and methods, have significantly advanced understanding of beta cell . Isolated islets from and pancreata serve as primary models, preserving the multicellular architecture and intercellular communications essential for glucose-stimulated insulin (GSIS). These preparations allow direct assessment of beta cell responses to nutrients and hormones, though challenges include donor variability and limited availability for islets. To address , immortalized cell lines such as MIN6, derived from a , and INS-1, from a , are extensively used; both lines exhibit glucose and GSIS akin to primary beta cells, facilitating high-throughput studies of insulin and signaling pathways. Complementary techniques like with the ratiometric dye Fura-2 enable real-time monitoring of cytosolic Ca²⁺ dynamics, a critical trigger for insulin , revealing oscillatory patterns during glucose stimulation in isolated beta cells and islets. Similarly, patch-clamp measures voltage-gated ion currents, such as Ca²⁺ and K⁺ channels, in single beta cells, demonstrating their role in membrane depolarization and ; for instance, recordings from intact islets show larger Ca²⁺ currents compared to dissociated cells, highlighting the influence of islet context. In vivo models, particularly genetically modified mice, model beta cell in the context of . The non-obese diabetic (NOD) mouse spontaneously develops through autoimmune destruction of beta cells, mimicking human insulitis and providing insights into immune-beta cell interactions; it remains a cornerstone for preclinical testing of immunomodulatory therapies. For , the db/db mouse, harboring a , exhibits , , and beta cell secretory deficits due to impaired GSIS and endoplasmic reticulum stress, closely paralleling human metabolic dysfunction. offers precise manipulation of beta cell activity in these models; expression of channelrhodopsin-2 in beta cells allows light-induced , enhancing insulin secretion and glycemic control in insulin-deficient mice without off-target effects. Such approaches reveal functional hierarchies within beta cell populations during glucose challenges. Omics technologies, notably single-cell sequencing (scRNA-seq), uncover transcriptomic heterogeneity and developmental states in beta cells. Single-cell sequencing (scRNA-seq) studies have identified maturity markers such as urocortin 3 (Ucn3) and glucose-6-phosphatase catalytic subunit 2 (G6pc2), distinguishing immature from functional adult beta cells and elucidating regulatory pathways for maturation. Advanced imaging techniques like two-photon enable non-invasive visualization of secretion dynamics in intact islets; by tracking fluorescently labeled insulin granules, it demonstrates polarized toward the vasculature, ensuring efficient hormone delivery and underscoring the spatial organization of beta cell function .

Advances in Regeneration and Stem Cell Therapy

One major advance in beta cell regeneration involves the differentiation of induced pluripotent stem cells (iPSCs) into functional beta-like cells using protocols that activate key transcription factors such as PDX1 and NEUROG3. Seminal seven-stage differentiation protocols developed in 2014 enable the scalable production of glucose-responsive beta cells from human pluripotent stem cells, mimicking embryonic pancreatic development through sequential activation of definitive endoderm, posterior foregut, pancreatic progenitor, and endocrine stages. These methods have been refined to yield up to 70-80% insulin-producing cells with robust glucose-stimulated insulin secretion, addressing the loss of beta cell mass in (T1D). Clinical translation of these iPSC-derived beta cells is exemplified by ' VX-880 (now zimislecel), an investigational allogeneic stem cell-derived cell infused intraportal in T1D patients with severe unawareness. Initiated in 2021, phase 1/2 trial data, published in 2025, demonstrate that 10 of 12 patients achieved insulin independence with sustained production and normalized hemoglobin A1c levels for at least one year post-infusion, indicating functional beta cell engraftment and glycemic control without exogenous insulin. Neogenesis approaches focus on stimulating new beta cell formation, including transdifferentiation from alpha cells using pharmacological agents. A 2015 study identified harmine, a DYRK1A inhibitor, as capable of inducing proliferation of adult beta cells and expanding beta cell mass in mice, improving glycemic control without toxicity. Combining harmine with GLP-1 receptor agonists like exendin-4 further enhances beta cell replication and promotes alpha-to-beta in islet xenografts in mice, increasing beta cell mass up to sevenfold. Recent studies have further elucidated the mechanism, showing that harmine promotes regeneration through cycling alpha cells serving as progenitors for new beta cells in treated pancreatic islets. By 2024, a phase 1 trial of oral harmine in healthy volunteers confirmed its safety and tolerability at doses supporting beta cell regeneration, paving the way for diabetes-specific studies. Beta cell protection strategies complement regeneration by delaying autoimmune destruction in T1D. , an anti-CD3 , was FDA-approved in November 2022 to delay clinical T1D onset in at-risk individuals aged 8 and older, preserving residual beta cell function for an average of two to three years as measured by sustained levels. In newly diagnosed patients, treatment similarly extends beta cell preservation, reducing insulin needs and stabilizing glycemic control. Despite these advances, challenges persist in achieving scalable, long-term beta cell regeneration. Key hurdles include inadequate vascularization of transplanted cell clusters, which limits delivery and cell post-engraftment, and immune rejection in non-immunosuppressed hosts, necessitating encapsulation or gene-editing for hypoimmunogenicity. A 2022 review emphasizes that while preclinical models show promise, translating these to humans requires overcoming variability in cell maturity, off-target proliferation, and integration into architecture to ensure physiological function.

Understanding Heterogeneity and Development

Beta cells originate from pancreatic progenitors marked by the PDX1 during early embryonic development, around weeks 4-5 of gestation, when the pancreatic buds form from the foregut endoderm. These progenitors undergo endocrine specification primarily through transient expression of NEUROG3, a key driver of differentiation into endocrine cell types, with the initial wave occurring between weeks 8 and 10 of . This process leads to the formation of fetal beta cells capable of insulin production, though their functional maturity is limited at this stage. Following birth, beta cell mass expands severalfold into adulthood, primarily through replication rather than neogenesis, with islets increasing in size but not number. Replication rates are highest during infancy, gradually declining thereafter, and exhibit significant inter-individual variability. Human beta cells are functionally immature at birth, showing poor glucose-stimulated insulin secretion despite insulin content; full glucose responsiveness develops postnatally, achieving adult-like thresholds by approximately 2-3 years of age through metabolic adaptations like enhanced and mitochondrial function. Under chronic stressors such as , , or , mature beta cells can dedifferentiate, losing identity markers (e.g., PDX1, MAFA) and reacquiring progenitor-like states via mechanisms including stress and oxidative damage. Beta cell populations exhibit heterogeneity in maturity, function, and , with subpopulations organized topologically within islets—such as central "hub" beta cells in the core that display higher connectivity and coordinated responses to glucose, contrasted with peripheral "mantle" regions showing gradients in secretory capacity. Recent 2025 studies using advanced and modeling have further demonstrated that this drives modular beta cell network activity during glucose responses. Single-cell transcriptomic studies have revealed these functional gradients, highlighting diverse subpopulations with varying insulin profiles and stress responses. Emerging research in the 2020s has elucidated epigenetic mechanisms regulating beta cell maturity, including 27 (H3K27ac) marks at active enhancers that promote maturation-associated ; disruptions in these marks, as seen in growth-restricted models, impair functional development. This heterogeneity contributes to aging-related vulnerabilities, where age-associated epigenetic remodeling accelerates in susceptible individuals, linking diverse beta cell states to risk through reduced adaptive capacity and increased propensity.

References

  1. https://training.seer.cancer.gov/anatomy/endocrine/glands/pancreas.html
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10046343/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC2857900/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC1569593/
  5. https://pubmed.ncbi.nlm.nih.gov/21920790/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3219158/
  7. https://medlineplus.gov/pancreaticdiseases.html
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5440564/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC9159263/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6715382/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5867580/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC3659747/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10239390/
  14. https://www.tandfonline.com/doi/full/10.1080/19382014.2019.1686323
  15. https://www.ncbi.nlm.nih.gov/books/NBK542302/
  16. https://journals.sagepub.com/doi/abs/10.1369/0022155415589119
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2894473/
  18. https://pubmed.ncbi.nlm.nih.gov/20657742/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC5866358/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC4324607/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC9768635/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3296007/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5878925/
  24. https://www.wava-amav.org/downloads/NHV_2017.pdf
  25. https://www.sciencedirect.com/topics/neuroscience/pancreatic-hormone
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC8238131/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC9534504/
  28. https://medlineplus.gov/genetics/gene/ins/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7476993/
  30. https://www.ncbi.nlm.nih.gov/books/NBK279029/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6463291/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC6542150/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9691942/
  34. https://pubmed.ncbi.nlm.nih.gov/12437983/
  35. https://www.pnas.org/doi/10.1073/pnas.0906587106
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8401130/
  37. https://www.sciencedirect.com/science/article/pii/0014579388809220
  38. https://pubmed.ncbi.nlm.nih.gov/10931181/
  39. https://pubmed.ncbi.nlm.nih.gov/15802374/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4856891/
  41. https://pubmed.ncbi.nlm.nih.gov/2185950/
  42. https://pubmed.ncbi.nlm.nih.gov/1999270/
  43. https://www.ncbi.nlm.nih.gov/books/NBK526026/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC5446389/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC6224910/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4662979/
  47. https://journals.physiology.org/doi/full/10.1152/ajpendo.00712.2009
  48. https://diabetesjournals.org/diabetes/article/73/8/1336/156780/Glucose-Transporters-Are-Key-Components-of-the
  49. https://www.nejm.org/doi/full/10.1056/NEJM200112133452412
  50. https://diabetesjournals.org/diabetes/article/54/11/3065/25478/Diabetes-and-Insulin-SecretionThe-ATP-Sensitive-K
  51. https://diabetesjournals.org/diabetes/article/55/2/441/12737/In-Vivo-and-In-Vitro-Glucose-Induced-Biphasic
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC10877731/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC4854503/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4853229/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC3712043/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4811990/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2628614/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC5997567/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC7604671/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC6732465/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC2518494/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC4456188/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC2528858/
  64. https://www.ncbi.nlm.nih.gov/books/NBK545201/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC2811454/
  66. https://www.ncbi.nlm.nih.gov/books/NBK525983/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC5927596/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC6170977/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC8900291/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC3526241/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC8735818/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC4899204/
  73. https://www.sciencedirect.com/science/article/pii/S2211124718315948
  74. https://www.nature.com/articles/s41574-024-00956-2
  75. https://www.sciencedirect.com/science/article/pii/S0196978122001899
  76. https://www.sciencedirect.com/science/article/pii/S0960982203003786
  77. https://link.springer.com/article/10.1007/s00125-019-4969-z
  78. https://www.gastrojournal.org/article/S0016-5085%2807%2900580-X/fulltext
  79. https://link.springer.com/article/10.1007/s00125-021-05565-6
  80. https://pubmed.ncbi.nlm.nih.gov/23973309/
  81. https://diabetesjournals.org/diabetes/article/56/4/1078/12991/Cx36-Mediated-Coupling-Reduces-Cell-Heterogeneity
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC11116783/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC3312399/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC11855905/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC3661605/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC11019645/
  87. https://www.sciencedirect.com/science/article/pii/S2211124725009453
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC5186767/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC10824181/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC11045915/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC11628569/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC8699655/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC1483155/
  94. https://rupress.org/jem/article/214/9/2591/42496/Induction-of-IAPP-amyloid-deposition-and
  95. https://www.sciencedirect.com/science/article/pii/S0002944011002707
  96. https://www.tandfonline.com/doi/full/10.1080/00325481.2020.1771047
  97. https://diabetesjournals.org/diabetes/article/70/11/2431/123866/Living-Dangerously-Protective-and-Harmful-ER
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC8601632/
  99. https://joe.bioscientifica.com/view/journals/joe/236/2/JOE-17-0516.xml
  100. https://www.science.org/doi/10.1126/sciadv.ads2905
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC4015541/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC8275893/
  103. https://diabetesjournals.org/care/article/40/8/1082/36735/The-rs7903146-Variant-in-the-TCF7L2-Gene-Increases
  104. https://www.sciencedirect.com/science/article/abs/pii/S0098299714000776
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC5013715/
  106. https://diabetesjournals.org/diabetes/article/73/1/75/153786/Single-Cell-Transcriptome-Profiling-of-Pancreatic
  107. https://www.nature.com/articles/s41467-025-65060-z
  108. https://www.nature.com/articles/s41467-023-41228-3
  109. https://journals.physiology.org/doi/full/10.1152/ajpendo.00649.2020
  110. https://www.nature.com/articles/s41586-024-07019-6
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC3574879/
  112. https://www.ncbi.nlm.nih.gov/books/NBK544299/
  113. https://www.ncbi.nlm.nih.gov/books/NBK278981/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC8986719/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC7614857/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC3498768/
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC3020366/
  118. https://pubmed.ncbi.nlm.nih.gov/12795645/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC4087792/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC10687782/
  121. https://www.ahajournals.org/doi/10.1161/01.CIR.94.9.2297
  122. https://www.ncbi.nlm.nih.gov/books/NBK459177/
  123. https://www.ncbi.nlm.nih.gov/books/NBK513225/
  124. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000SumR.pdf
  125. https://www.nature.com/articles/s41598-017-02838-2
  126. https://www.researchgate.net/publication/382765151_GLP-1_analogue_semaglutide_regulates_pancreatic_beta-cell_proliferation_via_PDX-1_expression_control
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC8736331/
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC8856523/
  129. https://www.sciencedirect.com/science/article/abs/pii/S0006295220302379
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC3410278/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC209533/
  132. https://www.e-dmj.org/journal/view.php?doi=10.4093/dmj.2018.0179
  133. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes
  134. https://www.sciencedirect.com/science/article/pii/S1600613522251387
  135. https://touchendocrinology.com/diabetes/journal-articles/progress-of-islet-transplantation-over-the-last-15-years/
  136. https://www.nejm.org/doi/full/10.1056/NEJMoa2506549
  137. https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes
  138. https://www.nature.com/articles/s41587-022-01219-z
  139. https://pubmed.ncbi.nlm.nih.gov/25303535/
  140. https://pubmed.ncbi.nlm.nih.gov/25211370/
  141. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-017-0694-z
  142. https://clinicaltrials.gov/study/NCT04786262
  143. https://www.nejm.org/doi/abs/10.1056/NEJMoa2506549
  144. https://diabetesjournals.org/diabetes/article/74/Supplement_1/140-OR/158407/140-OR-Durable-Glycemic-Control-and-Elimination-of
  145. https://pubmed.ncbi.nlm.nih.gov/25751815/
  146. https://www.science.org/doi/10.1126/scitranslmed.adg3456
  147. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00603-7
  148. https://www.mountsinai.org/about/newsroom/2024/mount-sinai-and-city-of-hope-scientists-first-to-demonstrate-a-combination-treatment-can-increase-human-insulin-producing-cells-in-vivo
  149. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf
  150. https://www.nejm.org/doi/full/10.1056/NEJMoa2308743
  151. https://pmc.ncbi.nlm.nih.gov/articles/PMC9353622/
  152. https://pmc.ncbi.nlm.nih.gov/articles/PMC5667467/
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC4376053/
  154. https://diabetesjournals.org/diabetes/article/62/10/3514/17837/Development-of-the-Human-Pancreas-From-Foregut-to
  155. https://diabetesjournals.org/diabetes/article/57/6/1584/40787/Cell-Replication-Is-the-Primary-Mechanism
  156. https://www.nature.com/articles/ncomms9084
  157. https://ec.bioscientifica.com/view/journals/ec/10/8/EC-21-0260.xml
  158. https://www.sciencedirect.com/science/article/pii/S0006349525004928
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC6768494/
  160. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.725131/full
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC7770033/
Add your contribution
Related Hubs
User Avatar
No comments yet.